Vector Science and Therapeutics Corp. is a Canada-based company. The Company develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions. The Company's product platforms and applications include Laparoscopic Atomizing Solution System (LASS) and Biomechanical Transdermal Device (BTP). The LASS Platform is an atomizing solution system designed to deliver therapeutics/anesthetics in a manner that infiltrates tissue to have a specific therapeutic effect. VectorMist is a catheter-based system designed for targeted delivery of atomized therapeutics directly into the surgical field during laparoscopic procedures. Vector BTP is an electrical biomechanical platform that functions as both a standalone therapeutic intervention and a drug delivery platform competing directly with sustained acoustic medicine devices and pulsed electromagnetic field devices in the regenerative and sports medicine segments.

Employees

Sector

Investment Holding Companies

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	CA$1.600	-2.44%	6,544
05/26/05	CA$1.640	0.00%	20,686
04/26/04	CA$1.640	+1.86%	2,87,435
31/26/31	CA$1.610	+3.21%	1,04,233
30/26/30	CA$1.560	+2.63%	3,17,489

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Delayed Toronto S.E. Other stock markets 07:07:52 06/08/2026 pm IST			5-day change	1st Jan Change
1.600 ^CAD	-2.44%		+2.56%	+3,100.00%

29/07	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
25/07	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI

Market Cap	18Cr 16Cr 15Cr 14Cr 26Cr 1.74TCr 26Cr 173.55Cr 68Cr 870.31Cr 69Cr 67Cr 2.88TCr	P/E 2024 *	-	P/E 2025	-0.29x
Enterprise Value	18Cr 16Cr 15Cr 13Cr 25Cr 1.71TCr 26Cr 170.82Cr 67Cr 856.6Cr 68Cr 66Cr 2.84TCr	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	79.62%	Yield 2024 *	-	Yield 2025	-

29/07	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
25/07	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
21/07	Vector Science to Build Distributor Network For Peptide Portfolio Commercialization	MT
17/07	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist	CI
17/07	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax	MT
15/07	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
09/07	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI
08/07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus	CI
01/07	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform	CI
12/06	Vector Science & Therapeutics Corp. Announces Appointment of Dexter Fowler as Chief Athletic Officer for Its Valor Platform	CI
08/06	Vector Science & Therapeutics Corp. Announces Appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors	CI
13/05	Vector Science and Therapeutics enters option to buy up to 15% of Lyogenesis Plus for up to $1 million	RE
12/05	Vector Science & Therapeutics Inc. Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC	CI

27/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
25/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
21/07	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels	AQ
17/07	Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist	AQ
15/07	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies	AQ

Vector Science and Therapeutics Corp. Share Price

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Valuation: Vector Science and Therapeutics Corp.

Chart: Vector Science and Therapeutics Corp.

Latest news : Vector Science and Therapeutics Corp.

Press Releases: Vector Science and Therapeutics Corp.

Quotes and Performance

Course Extremes

Latest insider transactions

Shell Companies

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-2.44%
1 week	+2.56%
Current month	-0.62%
1 month	-33.33%
3 months	+158.06%
6 months	+332.43%
Current year	+3,100.00%

1 week	1.51	1.65
1 month	1.46	2.48
Current year	0.35	2.65
1 year	0.35	2.65
3 years	0.03	2.65
5 years	0.03	2.65
10 years	0.03	2.65

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VECTOR SCIENCE AND THERAPEUTICS CORP.	-2.44%	+2.56%	+332.43%	+2,566.67%	18Cr
CHURCHILL CAPITAL CORP XI	+1.48%	+14.07%	-	-	89Cr
CENTIEL AG	+0.59%	+10.71%	+310.84%	-64.85%	69Cr
CHURCHILL CAPITAL CORP XII	+0.52%	+0.80%	-	-	60Cr
BAIN CAPITAL GSS INVESTMENT CORP.	+0.10%	-0.20%	-	-	60Cr
CANTOR EQUITY PARTNERS IV, INC.	-0.33%	-0.52%	-	-	59Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.17%	+1.77%	-	-	57Cr
DEEP FISSION, INC.	+9.14%	-1.98%	-	-	52Cr
CHURCHILL CAPITAL CORP XIII	+0.77%	0.00%	-	-	51Cr
Average	+0.98%	+3.20%	+321.64%	+1,250.91%	57.21Cr
Weighted average by Cap.	+1.19%	+4.04%	+315.39%	+489.62%

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-